Research programme: Gram-negative infection therapeutics - ContraFect/Rockefeller UniversityAlternative Names: Gram-negative lysins - Contrafect/Rockfeller University
Latest Information Update: 24 Nov 2016
At a glance
- Originator ContraFect; Rockefeller University
- Class Antibacterials; Endolysins
- Mechanism of Action Cell wall modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Gram-negative infections